Dual inhibitors for the treatment of alzheimer's disease

HK40137446APending Publication Date: 2026-09-11UNIV DE BARCELONA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125878
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-03-03
Filing Date
2026-07-08
Publication Date
2026-09-11
Patent Text Reader

Abstract

Compounds (I) are provided, where R1 and R2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula -[CH2]n- with n = 0, 1 or 2, or a biradical from a branched saturated (C2-C4)-alkylene chain; and A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a polycyclic 6- to 15-membered heterocyclic ring system having one or two O, S or N; wherein the C-radicals are unsubstituted or substituted. Compounds (I) are simultaneously inhibitors of soluble epoxide hydrolase and inhibitors of glutaminyl cyclase. Besides, they reduce the levels of pro-inflammatory cytokines in LPS stimulated BV2 cells, display low cytotoxicity, and have good BBB permeability. Thus, they are useful as multitarget compounds for the prevention or treatment of Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Compound (I) is provided, wherein R1 and R2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula -[CH2]n-, n = 0, 1, or 2, or a divalent group of a branched saturated (C2-C4)-alkylene chain; and A is a C-group from a non-aromatic polycyclic 6- to 15-membered carbon ring system, or a C-group from a polycyclic 6- to 15-membered heterocyclic system having one or both of O, S, or N; wherein the C-group is unsubstituted or substituted. Compound (I) is simultaneously an inhibitor of soluble epoxide hydrolase and an inhibitor of glutamine acyl cyclase. Furthermore, compound (I) reduces the levels of pro-inflammatory cytokines in LPS-stimulated BV2 cells, exhibiting low cytotoxicity and good BBB permeability. Therefore, they can be used as multi-target compounds for the prevention or treatment of Alzheimer's disease. Abstract

Claims

CLAIMSClaim 1. A compound of formula I, a stereoisomer or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt of any of them,wherein:R1and R2are each one a radical independently selected from the group consisting of H and (C1-C3)-alkyl;X is a biradical selected from the group consisting of a biradical of a linear methylene chain of formula -[CH2]n- with n = 0, 1 or 2, and a biradical from a branched saturated (C2-C4)-alkylene chain; andA is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a non-aromatic polycyclic 6- to 15-membered heterocyclic ring system having one or two heteroatoms in the ring, the heteroatoms being independently selected from O, S and N; wherein the C-radicals are unsubstituted or the C-radicals have one or more of their H atoms substituted by one or more substituents that are attached to any of the possible substitution positions, the substituents being independently selected from the group consisting of (C1-C4)-alkyl, O[(C1-C4)-alkyl], OH, F, Cl, Br, and I; on the proviso that radical A does not have any one of the three accompanying unsubstituted formulas, nor any of the possible substituted formulas derived thereof; andon the proviso that compound I does not have the accompanying formula lb.Claim 2. The compound according to claim 1, wherein A has a formula which is one of the unsubstituted accompanying formulas, or A has a formula which is a modification of the accompanying formulas in which one or more of the H atoms are substituted by one or more substituents which are attached to any of the possible substitution positions, and which are independently selected from the group consisting of (C1-C4)-alkyl, O[(C1-C4)- alkyl], OH, F, Cl, Br, and I.Claim 3. The compound according to claim 2, wherein A has one of the unsubstituted indicated formulas, or A has a formula which is a modification of the accompanying formulas in which one or more of the H atoms are substituted by one or more substituents which are attached to any of the possible substitution positions, and which are independently selected from the group consisting of CH3 , CH2CH3 , OH , F , and Cl.Claim 4. The compound according to any one of claims 1-3, wherein biradical X is selected from the group consisting of: a biradical of a linear methylene chain of formula -[CH2]n- with n = 0, 1 or 2; and the biradical -CH(CH3)- .Claim 5. The compound according to claim 4, wherein biradical X is a biradical of a linear methylene chain of formula -[CH2]n- with n = 0, 1 or 2.Claim 6. The compound according to claim 5, wherein n = 0, biradical X being a singlebond.Claim 7. The compound according to any one of claims 1-6, wherein R1is H or CH3 .Claim 8. The compound according to claim 7, wherein R1is H.Claim 9. The compound according to any one of claims 1-8, wherein R2is H or CH3 .Claim 10. The compound according to claim 9, wherein R2is CH3 .Claim 11. The compound according to claim 1 , having a formula independently selected from the group consisting of accompanying formulas la, Ic, Id, le, If, Ig, Ih, li, Ij, Ik, Im, Io, Ip, Iq, Ir, Is, It, lu, Iv, Iw, lx, ly, Iz, laa, lab and lac.Claim 12. A pharmaceutical composition comprising an effective amount of a compound as defined in any one of claims 1-11, together with adequate amounts of pharmaceutically acceptable excipients or carriers.Claim 13. A compound as defined in any one of claims 1-11, for use as an active pharmaceutical ingredient.Claim 14. A compound as defined in any one of claims 1-11 or as defined by accompanying formula lb, for use in the prevention or treatment of Alzheimer's disease in an animal, including a human.lb